{"success":true,"data":{"pressRelease":{"id":"142561","rtpr_id":"nGNE98QpF0-20260914","ticker":"NIKI","exchange":"NASDAQ","all_tickers":["NIKI"],"title":"Niki BioSolutions Accelerates Its Alzheimer’s Disease Testing Pipeline Through Strategic Bioinformatics and Statistical Analysis Partnership with Fios Genomics","author":"Globe Newswire","published_at":"2026-09-14T12:30:00.381Z","article_body":"Advanced multi-omics data analysis and biostatistical expertise to sharpen\ntarget and biomarker decisions across the platform\n\nPRINCETON, N.J., and NEW HAVEN, Conn., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Niki\nBioSolutions, Inc. (NASDAQ: NIKI) (“Niki” or the “Company”), a\nclinical-stage life sciences company focused on unmet medical needs and\ngenomic and biomarker testing solutions, today announced that its wholly owned\nsubsidiary, DiamiR Biosciences Corp. (“DiamiR”), has engaged Fios\nGenomics, a specialist provider of bioinformatics and biostatistics services,\nto perform bioinformatics and statistical analysis in support of the\nCompany’s Alzheimer’s disease program. Under the engagement, Fios Genomics\nwill analyze and interpret data generated across the program to help Niki\nBioSolutions advance its Alzheimer’s assays through the development\npipeline.\n\nAlzheimer’s disease affects tens of millions of people worldwide and remains\none of the most significant unmet needs in medicine. Robust, reproducible\nanalysis of complex biological datasets is essential to identifying meaningful\nbiological signals, validating targets and biomarkers, and making\nwell-informed decisions at each stage of development. Fios Genomics brings\ndeep experience in the analysis of genomic, transcriptomic, proteomic, and\nother large, complex biological datasets, together with rigorous statistical\nmethodology, to help translate raw data into actionable insight.\n\n“Engaging Fios Genomics is an important step forward for our Alzheimer’s\nprogram,” said Alidad Mireskandari, Ph.D., President and Chief Operating\nOfficer of Niki BioSolutions. “The datasets generated in this project are\nlarge and complex, and getting the analysis right is critical to the decisions\nwe make next. Fios Genomics has a strong track record of delivering\nhigh-quality, independent bioinformatics and statistical analysis for life\nsciences organizations, and its expertise allows our team to stay focused on\nadvancing the science. We look forward to a productive collaboration as we\nwork to bring new options to people at risk of or living with Alzheimer’s\ndisease.”\n\nAs part of the engagement, Fios Genomics will provide end-to-end analytical\nsupport, including data quality assessment, statistical analysis and\ninterpretation of current datasets, and the delivery of clear, decision-ready\nreports to Niki BioSolutions’ research and development team. The work is\nexpected to inform target and biomarker prioritization and support the design\nof subsequent validation studies within the pipeline.\n\nAbout Niki BioSolutions\n\nNiki BioSolutions is a clinical-stage life sciences company focused on unmet\nmedical needs and on providing high-quality genomic and biomarker testing\nsolutions to healthcare providers, research institutions, and life sciences\norganizations through its CLIA-certified, CAP-accredited laboratory. The\ncompany combines proprietary technologies with a commitment to scientific\nrigor to support precision medicine across a range of therapeutic areas,\nincluding brain health and oncology. Niki BioSolutions collaborates with\nleading academic centers, disease foundations, and biopharma companies.\n\nAbout Fios Genomics\n\nFios Genomics is a specialist provider of bioinformatics and biostatistics\nservices to the pharmaceutical, biotechnology, and academic sectors. The\ncompany supports research and development programs with data analysis and\ninterpretation across genomics, transcriptomics, proteomics, and other\nhigh-throughput data types, from early discovery through clinical development.\nFios Genomics is headquartered in Edinburgh, United Kingdom. For more\ninformation, visit www.fiosgenomics.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Forward-looking\nstatements often use words such as “believe,” “may,” “will,”\n“estimate,” “target,” “continue,” “anticipate,” “intend,”\n“expect,” “should,” “would,” “propose,” “plan,”\n“project,” “forecast,” “predict,” “potential,” “seek,”\n“future,” “outlook,” and similar variations and expressions.\nForward-looking statements are those that do not relate strictly to historical\nor current facts. Examples of forward-looking statements may include, among\nothers, Niki BioSolutions’ ability to successfully operate its business and\nprovide value to stockholders; Niki BioSolutions’ future financial, business\nand operating performance and goals; annualized recurring revenue and customer\nretention; ongoing or future ability to maintain or improve its financial\nposition, cash flows, and liquidity and its expected financial needs;\npotential financing and ability to obtain financing; acquisition strategy and\nproposed acquisitions and, if completed, their potential success and financial\ncontributions; strategy and strategic goals, including being able to\ncapitalize on opportunities; expectations relating to Niki BioSolutions and\nits industry, outlook and market trends; total addressable market and\nserviceable addressable market and related projections; plans, strategies and\nexpectations for increasing revenue and executing growth initiatives. Because\nforward-looking statements relate to the future, they are subject to inherent\nuncertainties, risks and changes in circumstances that are difficult to\npredict and many of which are outside of our control. Forward-looking\nstatements are not guarantees of future performance, and our actual results of\noperations, financial condition and liquidity and development of the\nindustries in which Niki BioSolutions operates may differ materially from\nthose made in or suggested by the forward-looking statements. Therefore,\ninvestors should not rely on any of these forward-looking statements. Factors\nthat may cause actual results to differ materially include changes in the\nmarkets in which Niki BioSolutions operates, the financial markets, economic,\nbusiness and regulatory factors, and other factors, such as Niki\nBioSolutions’ ability to execute on its strategies. More detailed\ninformation about risk factors can be found in the registration statement on\nForm S-4 filed with the Securities and Exchange Commission (the “SEC”) on\nOctober 6, 2025 (File No. 333-290742), and in other reports filed under the\ncompany’s prior name, Aptorum Group Limited, and that will be filed by Niki\nBioSolutions with the SEC. Niki BioSolutions does not undertake any duty to\nupdate forward-looking statements after the date of this press release.\n\nInvestor Contact:\n\nLytham Partners, LLC\nBen Shamsian\n646-829-9701\nshamsian@lythampartners.com","article_body_html":"","raw_payload":{"data":{"id":"nGNE98QpF0-20260914","title":"Niki BioSolutions Accelerates Its Alzheimer’s Disease Testing Pipeline Through Strategic Bioinformatics and Statistical Analysis Partnership with Fios Genomics","author":"Globe Newswire","ticker":"NIKI","created":"2026-09-14T12:30:00.381Z","tickers":["NIKI"],"exchange":"NASDAQ","article_body":"Advanced multi-omics data analysis and biostatistical expertise to sharpen\ntarget and biomarker decisions across the platform\n\nPRINCETON, N.J., and NEW HAVEN, Conn., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Niki\nBioSolutions, Inc. (NASDAQ: NIKI) (“Niki” or the “Company”), a\nclinical-stage life sciences company focused on unmet medical needs and\ngenomic and biomarker testing solutions, today announced that its wholly owned\nsubsidiary, DiamiR Biosciences Corp. (“DiamiR”), has engaged Fios\nGenomics, a specialist provider of bioinformatics and biostatistics services,\nto perform bioinformatics and statistical analysis in support of the\nCompany’s Alzheimer’s disease program. Under the engagement, Fios Genomics\nwill analyze and interpret data generated across the program to help Niki\nBioSolutions advance its Alzheimer’s assays through the development\npipeline.\n\nAlzheimer’s disease affects tens of millions of people worldwide and remains\none of the most significant unmet needs in medicine. Robust, reproducible\nanalysis of complex biological datasets is essential to identifying meaningful\nbiological signals, validating targets and biomarkers, and making\nwell-informed decisions at each stage of development. Fios Genomics brings\ndeep experience in the analysis of genomic, transcriptomic, proteomic, and\nother large, complex biological datasets, together with rigorous statistical\nmethodology, to help translate raw data into actionable insight.\n\n“Engaging Fios Genomics is an important step forward for our Alzheimer’s\nprogram,” said Alidad Mireskandari, Ph.D., President and Chief Operating\nOfficer of Niki BioSolutions. “The datasets generated in this project are\nlarge and complex, and getting the analysis right is critical to the decisions\nwe make next. Fios Genomics has a strong track record of delivering\nhigh-quality, independent bioinformatics and statistical analysis for life\nsciences organizations, and its expertise allows our team to stay focused on\nadvancing the science. We look forward to a productive collaboration as we\nwork to bring new options to people at risk of or living with Alzheimer’s\ndisease.”\n\nAs part of the engagement, Fios Genomics will provide end-to-end analytical\nsupport, including data quality assessment, statistical analysis and\ninterpretation of current datasets, and the delivery of clear, decision-ready\nreports to Niki BioSolutions’ research and development team. The work is\nexpected to inform target and biomarker prioritization and support the design\nof subsequent validation studies within the pipeline.\n\nAbout Niki BioSolutions\n\nNiki BioSolutions is a clinical-stage life sciences company focused on unmet\nmedical needs and on providing high-quality genomic and biomarker testing\nsolutions to healthcare providers, research institutions, and life sciences\norganizations through its CLIA-certified, CAP-accredited laboratory. The\ncompany combines proprietary technologies with a commitment to scientific\nrigor to support precision medicine across a range of therapeutic areas,\nincluding brain health and oncology. Niki BioSolutions collaborates with\nleading academic centers, disease foundations, and biopharma companies.\n\nAbout Fios Genomics\n\nFios Genomics is a specialist provider of bioinformatics and biostatistics\nservices to the pharmaceutical, biotechnology, and academic sectors. The\ncompany supports research and development programs with data analysis and\ninterpretation across genomics, transcriptomics, proteomics, and other\nhigh-throughput data types, from early discovery through clinical development.\nFios Genomics is headquartered in Edinburgh, United Kingdom. For more\ninformation, visit www.fiosgenomics.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Forward-looking\nstatements often use words such as “believe,” “may,” “will,”\n“estimate,” “target,” “continue,” “anticipate,” “intend,”\n“expect,” “should,” “would,” “propose,” “plan,”\n“project,” “forecast,” “predict,” “potential,” “seek,”\n“future,” “outlook,” and similar variations and expressions.\nForward-looking statements are those that do not relate strictly to historical\nor current facts. Examples of forward-looking statements may include, among\nothers, Niki BioSolutions’ ability to successfully operate its business and\nprovide value to stockholders; Niki BioSolutions’ future financial, business\nand operating performance and goals; annualized recurring revenue and customer\nretention; ongoing or future ability to maintain or improve its financial\nposition, cash flows, and liquidity and its expected financial needs;\npotential financing and ability to obtain financing; acquisition strategy and\nproposed acquisitions and, if completed, their potential success and financial\ncontributions; strategy and strategic goals, including being able to\ncapitalize on opportunities; expectations relating to Niki BioSolutions and\nits industry, outlook and market trends; total addressable market and\nserviceable addressable market and related projections; plans, strategies and\nexpectations for increasing revenue and executing growth initiatives. Because\nforward-looking statements relate to the future, they are subject to inherent\nuncertainties, risks and changes in circumstances that are difficult to\npredict and many of which are outside of our control. Forward-looking\nstatements are not guarantees of future performance, and our actual results of\noperations, financial condition and liquidity and development of the\nindustries in which Niki BioSolutions operates may differ materially from\nthose made in or suggested by the forward-looking statements. Therefore,\ninvestors should not rely on any of these forward-looking statements. Factors\nthat may cause actual results to differ materially include changes in the\nmarkets in which Niki BioSolutions operates, the financial markets, economic,\nbusiness and regulatory factors, and other factors, such as Niki\nBioSolutions’ ability to execute on its strategies. More detailed\ninformation about risk factors can be found in the registration statement on\nForm S-4 filed with the Securities and Exchange Commission (the “SEC”) on\nOctober 6, 2025 (File No. 333-290742), and in other reports filed under the\ncompany’s prior name, Aptorum Group Limited, and that will be filed by Niki\nBioSolutions with the SEC. Niki BioSolutions does not undertake any duty to\nupdate forward-looking statements after the date of this press release.\n\nInvestor Contact:\n\nLytham Partners, LLC\nBen Shamsian\n646-829-9701\nshamsian@lythampartners.com"},"type":"article","timestamp":"2026-09-14T12:30:00.473225629Z","server_sent_at_ms":1789389000473},"received_at":"2026-09-14T12:30:00.572Z","source_url":null},"analysis":{"id":"131387","press_release_id":"142561","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["No financial terms or deal value disclosed for the Fios Genomics engagement","Filer recently renamed from Aptorum Group Limited following an October 2025 Form S-4 registration — limited operating history under current identity"],"eventType":"partnership","narrative":"Niki BioSolutions announced that its wholly owned subsidiary DiamiR Biosciences has engaged Fios Genomics, an Edinburgh-based bioinformatics and biostatistics specialist, to support the company's Alzheimer's disease program.\n\nFios will provide end-to-end analytical support including data quality assessment, statistical analysis of current datasets, and decision-ready reports intended to inform target and biomarker prioritization and the design of subsequent validation studies.\n\nNo financial terms were disclosed, and the engagement does not include new clinical data; it is a routine service partnership for a clinical-stage diagnostics company rather than a catalyst event.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Pipeline-support service partnership with no financial terms — note for NIKI watchers but not a post-worthy catalyst."},"keyFigures":{},"quotedText":"Engaging Fios Genomics is an important step forward for our Alzheimer’s","namedEntities":{"people":[{"name":"Alidad Mireskandari, Ph.D.","role":"President and Chief Operating Officer, Niki BioSolutions"},{"name":"Ben Shamsian","role":"Investor relations contact, Lytham Partners"}],"products":["Alzheimer's disease assays","genomic and biomarker testing solutions"],"companies":[{"name":"Niki BioSolutions, Inc.","ticker":"NIKI","relationship":"filer"},{"name":"DiamiR Biosciences Corp.","relationship":"wholly owned subsidiary of the filer"},{"name":"Fios Genomics","relationship":"service partner (bioinformatics and biostatistics provider)"},{"name":"Lytham Partners, LLC","relationship":"investor relations firm"},{"name":"Aptorum Group Limited","relationship":"filer's prior name"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"A routine, non-binding service engagement (bioinformatics/biostatistics support) that modestly supports pipeline execution but carries no disclosed financial terms, revenue, or clinical data. It advances the Alzheimer's program analytically rather than changing its risk profile or the company's financial position."},"tickerRelevance":{"others":[],"primary":"NIKI"},"globalImportance":15,"audienceRelevance":12,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"micro-cap clinical-stage","eventGravity":"routine-service-partnership","sectorWeight":"health-care-diagnostics","issuerAuthored":true,"clinicalDataDisclosed":false,"financialTermsDisclosed":false}},"event_type":"partnership","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":2,"narrative":"Niki BioSolutions announced that its wholly owned subsidiary DiamiR Biosciences has engaged Fios Genomics, an Edinburgh-based bioinformatics and biostatistics specialist, to support the company's Alzheimer's disease program.\n\nFios will provide end-to-end analytical support including data quality assessment, statistical analysis of current datasets, and decision-ready reports intended to inform target and biomarker prioritization and the design of subsequent validation studies.\n\nNo financial terms were disclosed, and the engagement does not include new clinical data; it is a routine service partnership for a clinical-stage diagnostics company rather than a catalyst event.","key_figures":{},"named_entities":{"people":[{"name":"Alidad Mireskandari, Ph.D.","role":"President and Chief Operating Officer, Niki BioSolutions"},{"name":"Ben Shamsian","role":"Investor relations contact, Lytham Partners"}],"products":["Alzheimer's disease assays","genomic and biomarker testing solutions"],"companies":[{"name":"Niki BioSolutions, Inc.","ticker":"NIKI","relationship":"filer"},{"name":"DiamiR Biosciences Corp.","relationship":"wholly owned subsidiary of the filer"},{"name":"Fios Genomics","relationship":"service partner (bioinformatics and biostatistics provider)"},{"name":"Lytham Partners, LLC","relationship":"investor relations firm"},{"name":"Aptorum Group Limited","relationship":"filer's prior name"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-14T12:30:48.384Z","global_importance":15,"audience_relevance":12,"importance_components":{"tickerTier":"micro-cap clinical-stage","eventGravity":"routine-service-partnership","sectorWeight":"health-care-diagnostics","issuerAuthored":true,"clinicalDataDisclosed":false,"financialTermsDisclosed":false}},"durationMs":29955,"modelName":"glm-5.3-flash"}}